<div id="readability-page-1"><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/eyepoint-pharmaceuticals-inc-logo-1200x675.png/query-dj0yMDIyMTIyMjE1NTAyNA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1200" height="675" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/eyepoint-pharmaceuticals-inc-logo-1200x675.png/query-dj0yMDIyMTIyMjE1NTAyNA"/>Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) dropped 6.4% during mid-day trading on Monday . The stock traded as low as $9.96 and last traded at $10.02. Approximately 436,621 shares were traded during trading, a decline of 60% from the average daily volume of 1,101,198 shares. The stock had previously closed at $10.71.</p><h2>Analyst Ratings Changes</h2><p>EYPT has been the topic of several research reports. Chardan Capital dropped their price objective on EyePoint Pharmaceuticals from $39.00 to $28.00 and set a &#34;buy&#34; rating on the stock in a report on Tuesday, May 7th. Robert W. Baird lowered their price target on EyePoint Pharmaceuticals from $46.00 to $38.00 and set an &#34;outperform&#34; rating on the stock in a report on Wednesday, May 8th. Capital One Financial reissued an &#34;overweight&#34; rating on shares of EyePoint Pharmaceuticals in a report on Friday, February 16th. Mizuho lowered their price target on EyePoint Pharmaceuticals from $39.00 to $30.00 and set a &#34;buy&#34; rating on the stock in a report on Tuesday, May 7th. Finally, StockNews.com lowered EyePoint Pharmaceuticals from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Thursday, May 9th. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $33.71.</p><p><b>View Our Latest Stock Analysis on EyePoint Pharmaceuticals</b></p><h2>EyePoint Pharmaceuticals Stock Performance</h2><p>The stock's 50-day moving average price is $16.50 and its 200-day moving average price is $19.82. The company has a market capitalization of $514.55 million, a price-to-earnings ratio of -5.45 and a beta of 1.59. </p><p>EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.21). EyePoint Pharmaceuticals had a negative net margin of 157.77% and a negative return on equity of 49.94%. The company had revenue of $11.68 million for the quarter, compared to analyst estimates of $12.50 million. Analysts anticipate that EyePoint Pharmaceuticals, Inc. will post -2.14 earnings per share for the current year. </p><h2>Insider Activity</h2><p>In other news, Director David R. Guyer sold 11,625 shares of EyePoint Pharmaceuticals stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $12.65, for a total transaction of $147,056.25. Following the completion of the sale, the director now directly owns 5,550 shares in the company, valued at approximately $70,207.50. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, Director David R. Guyer sold 11,625 shares of EyePoint Pharmaceuticals stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $12.65, for a total transaction of $147,056.25. Following the completion of the transaction, the director now directly owns 5,550 shares in the company, valued at approximately $70,207.50. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, major shareholder Cormorant Asset Management, Lp acquired 850,000 shares of the business's stock in a transaction that occurred on Monday, May 6th. The shares were bought at an average price of $11.86 per share, with a total value of $10,081,000.00. Following the completion of the transaction, the insider now directly owns 8,325,000 shares in the company, valued at $98,734,500. The disclosure for this purchase can be found here. Insiders own 4.74% of the company's stock. </p><h2>Institutional Trading of EyePoint Pharmaceuticals</h2><p>Hedge funds and other institutional investors have recently bought and sold shares of the company. FNY Investment Advisers LLC purchased a new stake in EyePoint Pharmaceuticals in the 4th quarter worth approximately $27,000. Ameritas Investment Partners Inc. grew its stake in shares of EyePoint Pharmaceuticals by 44.0% during the 1st quarter. Ameritas Investment Partners Inc. now owns 3,719 shares of the company's stock valued at $77,000 after buying an additional 1,136 shares during the period. China Universal Asset Management Co. Ltd. purchased a new stake in shares of EyePoint Pharmaceuticals during the 4th quarter valued at $94,000. Sherbrooke Park Advisers LLC purchased a new stake in shares of EyePoint Pharmaceuticals during the 3rd quarter valued at $101,000. Finally, Tower Research Capital LLC TRC grew its stake in shares of EyePoint Pharmaceuticals by 36.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,724 shares of the company's stock valued at $109,000 after buying an additional 1,250 shares during the period. 99.41% of the stock is owned by hedge funds and other institutional investors. </p><h2>About EyePoint Pharmaceuticals</h2> (Get Free Report)<p>EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.</p><h2>See Also</h2><ul><li>Five stocks we like better than EyePoint Pharmaceuticals</li><li>How to Evaluate a Stock Before Buying </li><li>Why Smartsheet Stock is an Undervalued Gem of an Investment </li><li>Why Invest in 5G? How to Invest in 5G Stocks  </li><li>The Most Upgraded Stocks After the Q1 Earnings Season</li><li>How Technical Indicators Can Help You Find Oversold Stocks </li><li>What Is Risk Tolerance &amp; Why Is It Important?</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><p>→ Must-See: Elon’s New Invention is Absolutely Insane <span><span><span>(From InvestorPlace)</span> <span>(Ad)</span></span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MDg3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MDg3"/></span></p><h2>Should you invest $1,000 in EyePoint Pharmaceuticals right now?</h2><p>Before you consider EyePoint Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and EyePoint Pharmaceuticals wasn't on the list.</p><p>While EyePoint Pharmaceuticals currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p> </div>

NDAQ

EYPT

<p>EyePoint Pharmaceuticals (NASDAQ:EYPT) shares dropped 6.4% during mid-day trading, with a decline in trading volume. Analysts have revised the price target for the stock, and the company's recent earnings report showed a negative net margin. Insider activity includes a director selling shares and a major shareholder acquiring shares. Hedge funds and institutional investors have also been buying and selling shares. The stock's 50-day moving average is $16.50.</p>

EyePoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 6.4%